Pressmeddelande -
Sortina Pharma welcomes world-renowned neuro-oncologist professor Petra Hamerlik as scientific advisor
..............................................................
GU Ventures share news and information about the business, its companies, and alumni companies:
..............................................................
Sortina Pharma, a pioneer in developing next-generation therapies for cancer proudly announces the appointment of leading neuro-oncologist Professor Petra Hamerlik to its Scientific Advisory Board. With an eminent career marked by groundbreaking contributions to neuro-oncology, Petra’s expertise will play a pivotal role in advancing Sortina’s mission to transform the treatment landscape for aggressive cancers like glioblastoma.
Petra brings a wealth of experience from the University of Copenhagen and the University of Manchester as well as AstraZeneca, establishing a reputation as a thought leader in the field. Her deep understanding of the clinical challenges and opportunities in neuro-oncology aligns perfectly with Sortina’s vision of delivering life-saving treatments to patients with limited options.
"We are honored to welcome Professor Petra Hamerlik” says Sara Rhost, CEO of Sortina Pharma. “Petra’s unparalleled expertise and strategic insights will be instrumental in accelerating the development of our first-in-class therapies, bringing hope to patients facing some of the most devastating cancer diagnoses.”
“I am truly excited to join Sortina Pharma as a Scientific Advisor, Petra says. ”This collaboration presents a unique opportunity to leverage my expertise in translational neuro-oncology to contribute to the development of innovative therapies. I firmly believe that together we can make significant strides in addressing the pressing challenges faced by patients with aggressive cancers like glioblastoma. I'm looking forward to working alongside the talented team at Sortina to bring hope and new treatment options to those in need”.
About Sortina Pharma
Sortina Pharma is a pre-clinical drug development company founded in 2020 based on research originating from professor Göran Landberg´s research group at Gothenburg University. The company develops anti-sortilin small molecule inhibitors as well-tolerated oral treatment for cancer patients, with or at risk of recurrencies and metastases, aiming to increase survival rates of incurable sortilin positive cancers such as glioblastoma, breast cancer, melanoma and pancreatic cancer.
For more information, please visit:
https://www.sortinapharma.com/
Ämnen
Kategorier
Om GU Ventures AB
GU Ventures bygger företag av banbrytande idéer som kan forma en bättre morgondag och är topprankad av UBI Global Index som en av världens 20 ledande universitetsdrivna inkubatorer. Vi finansierar och utvecklar nya innovativa affärsidéer med kopplingar till Göteborgs universitet, som är ett av norra Europas största universitet. Vårt uppdrag är att kommersialisera dessa innovationer, så att det leder till användning av forskning och kompetens, förnyelse av näringslivet, skapande av jobb och hållbar tillväxt. Vårt passionerade team av företagsbyggare, finansexperter, IP och juridisk talang supporterar dedikerat våra företag och säkerställer deras framgång.
Sedan startpunkten 1995 har GU Ventures utvecklat över 240 nya affärsidéer, varav 140 bedriver verksamhet idag och varav 15 är listade. Vår portfölj består av 80-tal innehav och ett antal projekt.
I den senaste undersökningen matchar 87% av företagen de globala hållbarhetsmål som ställts av FN. GU Ventures ägs helt av den svenska staten och förvaltas av Göteborgs universitet. Läs gärna mer på: www.guventures.com.
